Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma.
bridging
cyclophosphamide
etoposide
extramedullary disease
multiple myeloma
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
20
12
2022
received:
26
10
2022
accepted:
16
01
2023
medline:
11
8
2023
pubmed:
22
1
2023
entrez:
21
1
2023
Statut:
ppublish
Résumé
Patients with relapsed refractory multiple myeloma (RRMM) that are triple-exposed to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies have a poor prognosis. Standard treatment for these patients has not been established. Patients with extramedullary disease or secondary plasma cell leukemia often display high tumor cell proliferation and might therefore be susceptible to chemotherapy. While current regimens are often platinum-based, we present single-center data on 70 patients with RRMM who were treated with cyclophosphamide, etoposide, and dexamethasone (CED) after a median of four lines of therapy. An overall response rate of 52% was achieved after 1-6 cycles, with 23% of patients having a very good partial response. Comparable response rates and survival were observed in patients with extramedullary disease and high-risk cytogenetics. Treatment resulted in non-hematological °III-IV adverse events in 31% of patients. No treatment-related deaths occurred. The median progression-free and overall survival were 6.2 and 10.9 months, respectively. 23% of patients were bridged to autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T cell therapy. In summary, CED is an effective treatment regimen for RRMM cases with a tolerable safety profile and suitable as bridging therapy to CAR T cell treatment and ASCT.
Substances chimiques
Cyclophosphamide
8N3DW7272P
Etoposide
6PLQ3CP4P3
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
453-462Informations de copyright
© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
Références
Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):1-12. https://doi.org/10.1038/s41408-018-0141-0
Bazarbachi AH, Al Hamed R, Malard F, Harousseau J.-L, Mohty M. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33(10):2343-2357. https://doi.org/10.1038/s41375-019-0561-2
Ravi P, Kumar SK, Cerhan JR, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8(3):1-7. https://doi.org/10.1038/s41408-018-0065-8
Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-2275. https://doi.org/10.1038/s41375-019-0435-7
Mateos M.-V, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371-1376. https://doi.org/10.1038/s41375-022-01531-2
Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34(1):1-20.
Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325-330. https://doi.org/10.1093/annonc/mdp329
Lakshman A, Singh PP, Rajkumar SV, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol. 2018;93(2):179-186. https://doi.org/10.1002/ajh.24954
Alsouqi A, Khan M, Dhakal B, et al. KD-PACE salvage therapy for aggressive relapsed refractory multiple myeloma, plasma cell leukemia and extramedullary myeloma. Clin Lymphoma, Myeloma & Leukemia. 2021;21(8):526-535. https://doi.org/10.1016/j.clml.2021.03.013
Zhou X, Ruckdeschel A, Peter J, et al. Salvage therapy with “Dara-KDT-P (A) CE” in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma. Hematol Oncol. 2022;40(2):202-211. https://doi.org/10.1002/hon.2949
Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207-221. https://doi.org/10.1016/s1470-2045(19)30788-0
Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021;127(22):4198-4212. https://doi.org/10.1002/cncr.33809
Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727-738. https://doi.org/10.1056/nejmoa1903455
Creixenti JB, Mateos M.-V, Oriol A, et al. HORIZON (OP-106) versus MAMMOTH: an indirect comparison of efficacy outcomes for patients with relapsed/refractory multiple myeloma refractory (RRMM) to anti-CD38 monoclonal antibody therapy treated with melflufen plus dexamethasone versus conventional agents. Blood. 2020;136(Suppl 1):2-4. https://doi.org/10.1182/blood-2020-137164
Anderson J, Larry D, Munshi NC, et al. Idecabtagene Vicleucel (Ide-cel, Bb2121), a BCMA-Directed CAR T Cell Therapy, in Relapsed and Refractory Multiple Myeloma: Updated KarMMa Results. Wolters Kluwer Health; 2021.
Lemieux E, Hulin C, Caillot D, et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant. 2013;19(3):445-449. https://doi.org/10.1016/j.bbmt.2012.11.013
Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood. 2001;98(13):3846-3848. https://doi.org/10.1182/blood.v98.13.3846
Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337-1341. https://doi.org/10.1038/leu.2009.26
Lazzarino M, Corso A, Barbarano L, et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant. 2001;28(9):835-839. https://doi.org/10.1038/sj.bmt.1703240
Nadiminti K, Strouse C, Sidiqi MH, et al. Impact of chemotherapy based induction using dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) versus novel agent induction in patients undergoing tandem autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Biol Blood Marrow Transplant. 2019;25(3):S399-S400. https://doi.org/10.1016/j.bbmt.2018.12.813
Benson DM, Jr, Elder PJ, Lin TS, et al. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leukemia Res. 2007;31(8):1069-1075. https://doi.org/10.1016/j.leukres.2006.09.021
Park S, Lee SJ, Jung CW, et al. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. Ann Hematol. 2014;93(1):99-105. https://doi.org/10.1007/s00277-013-1952-5
Barlogie B, Anaissie E, Van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138(2):176-185. https://doi.org/10.1111/j.1365-2141.2007.06639.x
Zhou X, Steinhardt MJ, Grathwohl D, et al. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom-PAD-Dara”) in relapsed/refractory multiple myeloma. Cancer Med. 2020;9(16):5819-5826. https://doi.org/10.1002/cam4.3209
Moreau P, Garfall AL, van de Donk NW, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495-505. https://doi.org/10.1056/nejmoa2203478
Chari A, Berdeja JG, Oriol A, et al. A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl 1):40-41. https://doi.org/10.1182/blood-2020-133873
Berdeja JG, Krishnan AY, Oriol A, et al. Updated Results of a Phase 1, First-In-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D)× CD3 Bispecific Antibody, in Relapsed/refractory Multiple Myeloma (MM). Wolters Kluwer Health; 2021.
Jelinek T, Sevcikova T, Zihala D, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2022;36(1):288-291. https://doi.org/10.1038/s41375-021-01343-w
Rytlewski J, Fuller J, Mertz DR, et al. Correlative Analysis to Define Patient Profiles Associated with Manufacturing and Clinical Endpoints in Relapsed/refractory Multiple Myeloma (RRMM) Patients Treated with Idecabtagene Vicleucel (Ide-cel; Bb2121), an Anti-BCMA CAR T Cell Therapy. American Society of Clinical Oncology; 2022.